Alpha Tau Medical stock set to join two Tel Aviv indexes

Alpha Tau Medical said on Thursday, October 29, that its ordinary shares will be included in the Tel Aviv Stock Exchange's TA-90 and TA-125 indexes from November 5. The company announced the change in a press release carried by GlobeNewswire.

Index inclusion raises visibility

Alpha Tau said funds that track the two benchmarks are expected to add its shares to their holdings. The company described the TA-125 as a benchmark followed by many Israeli investors and said the inclusion could increase visibility with local institutional investors, broaden the shareholder base and support trading activity. Those potential effects are management expectations rather than confirmed outcomes.

Clinical development remains central

Alpha Tau is developing Alpha DaRT, a localized alpha-radiation treatment designed to deliver radium-224 sources directly into solid tumors. The company said the treatment has marketing approval in Japan for certain head and neck cancers and in Israel for products intended to treat squamous cell carcinoma of the skin and oral cavity. Outside those areas, Alpha DaRT remains subject to clinical and regulatory development.

Specialized oncology platform

Alpha Tau Medical is an Israeli oncology therapeutics company focused on researching, developing and potentially commercializing Alpha DaRT for solid tumors. Its approach uses intratumoral delivery of radioactive sources intended to concentrate alpha radiation in the tumor while limiting exposure to nearby tissue. The company therefore occupies a specialized position within oncology rather than operating as a broad medical-device supplier.

Israeli equities remain closely linked to developments in the TA-35 market environment.

More news and analyses on Alpha Tau Medical stock.